UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 17, 2022
Signify Health, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| | | | | | | | |
| Delaware | 001-40028 | 85-3481223 |
| (State of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |
| | |
| 800 Connecticut Avenue | | |
Norwalk, CT (Address of Principal Executive Offices) | | 06854 (Zip Code) |
Registrant’s telephone number, including area code: (203) 541-4600
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading symbol | | Name of each exchange on which registered |
| Class A common stock, par value $0.01 per Share | | SGFY | | New York Stock Exchange |
| | | | | |
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| Emerging growth company ☒ |
| |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐ |
Item 5.02. Departure of Certain Officers; Appointment of Certain Officers.
Effective July 20, 2022, Peter Boumenot, the Company���s Chief Product Officer, will be leaving the Company to pursue other interests under circumstances entitling him to severance under his employment agreement.
Item 8.01. Other Events.
On June 22, 2022, the Company announced that Paymon Farazi will be joining the Company as Chief Product Officer responsible for product strategy, development and marketing across the Company’s business segments.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| | SIGNIFY HEALTH, INC. |
| | |
| Date: June 22, 2022 | By: | /s/ Steve Senneff |
| | Name: Steve Senneff |
| | Title: President & Chief Financial and Administrative Officer |
| | |
| | |
| | |
| | |
| | |
